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Abstract
Parkinson’s is a neurodegenerative disease, which is common all over the world. 
Various aspect like damages of reactive oxygen species, excitotoxicity, mitochon-
drial dysfunction, and inflammation-facilitated cell damages are included in the 
etiology of disease. Good-balanced nutrition is an important part involved in the 
body health maintenance and reduction in the risk of chronic diseases. Genus 
Mucuna falls under family Fabaceae, containing high contents of L-DOPA (com-
monly used as an anti-Parkinson drug). Plant-based medicines are the superfluous 
source of polyphenols, flavonoids, carotenoids, antioxidants (ROS and RNS), 
terpenoids, isoflavonoids, and other biologically active phytochemicals. All these 
molecules have health beneficial effects with superlative pharmaceutical values. 
The existing chapter summaries to determine the influence of different nutritional, 
anti-nutritional, and medicinal potential of the Mucuna species present in India and 
its significance in the management of Parkinson’s disease (Shaking Palsy) as well as 
other medicinal values. It also covers various treatment models used in studying the 
Parkinson’s disease like Drosophila melanogaster, zebrafish, mice, rat, and humans. 
This chapter also focuses light on the neurosurgical treatments used in the treat-
ment of Parkinson’s disease. This study concluded that the use of Mucuna seeds for 
the treatment of Parkinson’s disease is the best choice besides chemical drugs and 
other therapies.
Keywords: Kampavata, L-DOPA, Mucuna, neuroprotective, experimental models, 
neurosurgical remedy
1. Introduction
Research in plant-based medicine is gaining much more attention due to its lack 
of side effects, its large availability, and its multiple medicinal applications. In the 
past few years, this has also increased people’s awareness toward functional food, 
thus enhancing the consumption rate of legumes enormously [1]. The attention 
toward Mucuna improved colossally after 1937 when it was initially revealed that a 
huge quantity of levodopa is present in it. Genus Mucuna, which is familiar by dif-
ferent names (like: velvet beans, sea beans, cowitch, buffalo beans, cowhage, atma-
gupta, kapikachu, and dopa bean), is one of the conventional medicine performing 
crucial roles in both health and disease management. Mucuna is an excellent 
source of proteins, starch, micronutrients, dietary fiber, and bioactive compounds 
(L-DOPA), which play a great role in the traditional as well as modern medicine all 
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over the world against Parkinson’s disease. The genus Mucuna belongs to the family 
Leguminosae distributed throughout the tropical and subtropical regions of various 
countries of the world comprising hundreds of species [2]. Recently, Pulikkalpura 
et al. [3] and Patil et al. [4, 5] studied the occurrence and biochemical activities of 
various Mucuna species in India.
Plant-based remedies are most beneficial remedies, having a cumulative effect of 
phytochemical and other bioactive components obtained from plants. Mucuna has 
various actions like antioxidant activity, anti-inflammatory activity, wound-healing 
activity, and activity against snake bite. Along with all this, Mucuna is also rich in 
nutritional and anti-nutritional compounds (rich in minerals) [6]. Mucuna is also 
well known for nematicidic effects and also possesses notable allelopathic activity, 
which was reported by Gliessman et al. [7]. In countries like Guatemala and Mexico, 
it is used as a coffee substitute. Along with that, in some countries (lower hills of the 
eastern country and Himalayas), it is commonly consumed as vegetable beans after 
frying and boiling. Mucuna seed powder has been used in active management of 
Parkinson’s disease in several countries due to its L-DOPA content.
In early health care system of India, Parkinson’s disease (PD) is known as 
“Kampavata”, which is a common neurological disorder related to neuromelanin 
containing nigrostriatal dopaminergic neuronal loss. Kampa means tremor and 
vata means lack of muscular movement. It was found via door-to-door survey 
in Bangalore (Karnataka, India) that 76 per 100, 000 (age adjusted) and 33 per 
100,000 (crude prevalence) people suffered from Parkinsonism [8]. Out of that, 
5–10% of individuals having PD belong to families with history of genetic disor-
ders [9, 10]. The disease commonly occurs in the age group of 60–80. A survey 
on Parsi community in Mumbai shows that they were diminutively stable to PD 
[8]. Diagnosis of disease is sometimes difficult by clinical method, which involves 
analysis by considering large number of motor and non-motor symptoms in PD 
patients. PD is caused due to decrease in dopaminergic neurons in the substantia 
nigra pars compacta (SNpc) part of the brain, which leads to motor symptoms 
including rigidity, bradykinesia, tremor, and development of some non-motor 
symptoms in later stages of the disease. Although there is significant number of 
improvements in the medicinal and surgical actions against PD, scientists have 
not yet identified definite targets for disease management. According to research 
by Ramanan and Saykin, neurodegeneration is divided in to four main levels out 
of which aggregation and accumulation of abnormal or misfolded mutated pro-
teins is crucial [11]. Some reports examine that oxidative stress (OS) and neuro-
inflammation (NIF) are the main reasons of neurodegenerative disease. Thus, to 
tackle these neurodegenerative disorders, researchers have diverted their attention 
toward finding oxidative stress enzymes and pathogenesis of PD. Abraham et al. 
studied 115 cases of PD and concluded that catalase (CAT), superoxide dismutase 
(SOD), glutathione peroxidase (G-Px), and glucose-6-phosphate dehydrogenase 
(G6PD) levels are present in greater quantities in PD patients as compared to the 
control patients [11]. Various oxidative stress enzymes, pro-inflammatory cyto-
kines, proteinase, reactive oxygen intermediates, and complement proteins are 
secreted by the immune cells against the neuronal cell damage response, which 
leads to inflammation. Along with mitochondrial dysfunction, altered proteolysis, 
oxidative damage of cells and Lewy bodies’ formation are some of the symptoms of 
Parkinson’s disease.
There are various strategies for the management for PD but there is no complete 
cure for this disease. The only management of the lowered dopamine levels is to 
control various metabolic inhibitions and enhancement pathways, preventing 
degeneration of neurons and other non-dopaminergic (surgelogical) treatment. 
L-DOPA (L-3,4 dihydroxy phenylalanine) is a non-protein amino acid used in the 
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treatment of Parkinson’s disease. It acts as precursor of dopamine, norepinephrine 
(noradrenaline), and epinephrine (adrenaline). It is synthesized by plants, ani-
mals, and microbes (bacterial and fungus) and has a different role in each source. 
Chemical synthesis of L-DOPA is easy but the purification of L and D forms is 
slightly complicated and expensive. Synthetic L-DOPA is considered as anti-nutri-
tional factor and its consumption causes abdominal distention, vomiting, dyski-
nesia, nausea, etc. This happens when L-DOPA is converted to dopamine in the 
peripheral nervous system by enzyme dopa decarboxylase. Whereas, L-dopa is also 
used as the treatment against infertility recovering the spermatogenic harm to some 
extent. Numerous other secondary metabolites produced by plants like flavonoids 
and phenolics illustrate strong anti-inflammatory and antioxidant potentials, which 
have a significant role in the management of health and disease of human beings.
The current book chapter is focused on the use of plant source of L-DOPA and 
neuroprotective potential of magical dopa beans and their special prominence in 
Parkinson’s disease treatment. Along with this we have also focused on the models 
and other treatments used in treating Parkinson’s disease.
2. Treatment strategies of Parkinson’s disease
2.1 Neuroprotective potential of Mucuna
Parkinson’s disease (PD) was initially discovered by Dr. James Parkinson in 1817; 
it is a chronic neurological disorder triggered by a progressive loss of dopaminergic 
neurons present in the nigrostriatal part of the brain and found to be common 
in U.S [12]. In 1970, only few effective drugs were available for treatment of the 
PD but there is no such therapy yet that completely treats PD. Only thing we can 
do is to stop the progression of Parkinson’s disease or delay the of PD by replace-
ment of dopaminergic neuron or by mimicking the neuron by using substituent. 
Management of PD is mainly divided into two categories: first involves improving 
symptomatic treatment of motor and non-motor types of symptoms and second 
will be addressing potential causes of PD. Firstly in 1978 Vaidya et al., published 
the report that PD can be treated by Mucuna extract, a natural source of levodopa 
having better activity than the synthetic version of levodopa drug [13]. Similar 
studies were reported in 1990 and 1994 by Kempster et al. and Rabey et al. [14, 15]. 
L-DOPA is a precursor of dopamine (Figure 1), norepinephrine (noradrenaline), 
Figure 1. 
Synthesis pathway of L-DOPA, dopamine and further metabolites.
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and epinephrine (adrenaline), together known as catecholamines. The dopamine 
produced cannot cross the blood–brain barrier but L-DOPA can. Outside the brain, 
L-DOPA can directly be converted to 3-O-methyldopa (3-OMD) by catechol-O-
methyl transferase (COM T) and then further to vanillactic acid (VLA), which 
leads to primary same side effect. To avoid this conversion, standard clinical 
practices use DOPA decarboxylase inhibitor such as carbidopa or benserazide and 
often a catechol-O-methyl transferase (COMT) inhibitor [16–18]. L-DOPA present 
in Mucuna plant (anti-Parkinson’s drug) [19–21] helps to produce dopamine. Along 
with L-DOPA, the reactive oxygen species (ROS) and reactive nitrogen species 
(RNS) produced by Mucuna are stress-producing free radicals playing a great role in 
the physiological functioning of the body [21–30]. The content of antioxidant com-
pounds using different solvents in different species of Mucuna, the concentration of 
antioxidants and other phytochemicals are extremely different. Ethanolic extract of 
Mucuna seed shows good antioxidant activity due to high phenolic content as com-
pared to methanol, water, and acetone [31]. Some reports also conclude that water 
is as universal solvent, which shows the significant quantity of phenolic, flavonoids, 
and strong antioxidants which have the ability to scavenge free radicals using differ-
ent assays. LCMS (liquid chromatography mass spectrophotometry) report of four 
different species (Table 1) shows that there are various components like phenolic 
flavonoids and bioactive compounds present in the Mucuna that are responsible for 
the production of reactive species [32]. Along with L-DOPA and antioxidants, other 
secondary metabolites like phenolics, flavonoids, vitamins, enzymes, and protein 
also have a cumulative effect in the management of PD. Few reports on Mucuna 
show correlation between L-DOPA, protein, and carbohydrates. The use of plants 
for the treatment of PD is more beneficial than chemically manufactured L-dopa 
due to its high potential required in the levo and dextro form purification. It is also 
studied that various compounds present in Mucuna are responsible for the antimi-
crobial action, which can be utilized in dealing with various infectious diseases and 
ulcers [31, 32, 44]. Experiments on various plant pathogens suggest that methanolic 
extract of Mucuna pruriens seeds showed the highest antimicrobial activity [45]. A 
similar type of study done by Pujari et al. also determined that methanol extracts 
of Mucuna pruriens seeds were found to have the best inhibiting activity among all 
scrutinized pathogens as compared to ethanol and acetone solvents. But alcoholic 
extract of Mucuna pruriens (L.) leaves has significant antioxidant and antibacterial 
Sr.no Mucuna species Reference
1 Mucuna imbricata [32]
2 Mucuna macrocarpa [33]
3 Mucuna monosperma [34]
4 Mucuna Bactetia [35]
5 Mucuna sanjepee [36]
6 Mucuna Autripuria [37]
7 Mucuna Latiparica [5]
8 Mucuna prurience [3, 6, 20, 21, 24, 38–43]
9 M. nigricans [5]
10 M. gigentea [5]
11 Dhanwantari [5]
Table 1. 
Different species of Mucuna studied till date.
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activity [45]. Dopaminergic agonists or dopamine replacement therapy is a common 
and most effective way to cure PD. It decreases the signs of disease by sustaining 
the level of dopamine; however, it cannot regenerate or halt the degeneration. It 
only replaces or mimics dopamine by inhibiting its breakdown. Apomorphine, 
bromocriptine, pergolide, piribedil, pramipexole, and ropinirole are some dopami-
nergic agonists mainly used to heal the PD. All these bioactive compounds present 
in the Mucuna species have cumulative effect in the treatment of PD. Mucuna 
pruriens is a species from the Fabaceae family and Faboideae subfamily. M. pruriens 
is an annual twinning plant in bushes, hedges, and one of the popular medicinal 
plants indigenous to tropical countries like India [42]. It is useful in relieving 
inflammation, delirium, neuropathy, cephalalgia, and general debility, nephropa-
thy, dysmenorrhea, amenorrhea, ulcers, constipation, elephantiasis, consumption, 
helminthiasis, fever, and dropsy. The trichomes of pods contain serotonin and 
mucunain. The trichomes are used as anthelmintic. Seeds contain glutathione, gallic 
acid, levodopa (4-3, 4-dihydroxy phenylalanine), lecithin, prurenine, prurenidine, 
glycosides, nicotine, minerals, and dark brown viscous oil [42].
2.2 Experimental models studied for PD
Natural products are valuable sources of bioactive compounds that can be 
exploited for novel therapeutic potential in PD pathogenesis. There are number of 
publications reported till now dealing with experiments on hundreds of compounds 
from various plant species for their different activity in curing the Parkinson’s dis-
ease [46]. However, rapid screening of plant-derived natural products and charac-
terization of bioactive compounds is a challenging job. This problem was combated 
by using Drosophila melanogaster and zebrafish as experimental models at initial 
stages then followed by studies on various experimental models like, C. elegans, 
mice/rat, and also cell lines (e.g., murine BV-2 microglia and human SH-SY5Y 
neuroblastoma cells). Few verdicts using different models are listed underneath.
2.2.1 Drosophila melanogaster
Drosophila melanogaster, universally familiar as the fruit fly, have turned up as 
an outstanding model for human neurodegenerative diseases, comprising PD. Due 
to their high degree of conserved molecular pathways with mammalian models, 
Drosophila PD models serve to be an inexpensive solution to pilot stages of target 
validation in the drug discovery pipeline. Fruit fly acts as a screening platform to 
evaluate the therapeutic potential of phytochemicals from natural extracts against 
PD [47]. Drosophila melanogaster is a persuasive tool to explore molecular facets and 
physiopathology of Parkinson’s disease (PD) [48]. There are studies that compare 
the effects of L-DOPA vs. MP extract using a Drosophila model of autosomal 
recessive PD in which flies carried a mutation in the PTEN-induced putative kinase 
1 (PINK-1) gene [49]. Their observations illustrates that Drosophila fed on MP had a 
significantly extended lifespan, showed a restored olfactory response and improved 
climbing behavior compared to flies that consumed L-DOPA.
2.2.2 Zebra fish (Danio rerio)
Owing to its large number of favorable properties, Zebra fish has been used 
widely as experimental animal for various diseases. Zebra fish are inexpensive, easy 
to conserve, develop rapidly, and breed in large quantities. Larval zebra fish are also 
extensively used in toxicity screens since they have a permeable skin through which 
substances added in the rearing medium are effortlessly taken up. This permits for 
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greater control over dosage and ease of administering substances to large numbers 
of animals. Furthermore, larval behaviors can be exploited in assays to test the 
effects of the treatment. Being a vertebrate, the central nervous system of larval 
zebra fish expressions an extremely homologous to humans. Therefore, toxicology 
studies performed on larval zebra fish can be very helpful in deciding the putative 
targets in humans [50]. Thus Danio rerio commonly known as zebrafish is a charm-
ing popular animal model for treatments in neuropharmacology and pharmaco-
genetics. Both the adult and larval zebrafish are presently studied to increase the 
understanding of central nervous system’s function and dysfunction [51]. There 
are various studied reports by Gerlai et al. on the latent learning, behavior, and 
memory alteration of adult zebrafish [51–55]. Apart from fish, there are several 
other experimental models.
2.2.3 Mice/rat/rodents
Many clinical trials have been done on herbal extract and their isolated com-
pound, which has opened a new scenario in the area of PD. The models of PD are 
induced by different chemical compounds like 6-OHDA, rotenone, and MPTP 
based on the aim of the experiment. Singh et al. investigated the effect of ethanolic 
extract of Mucuna pruriens (Mp) on the reduction of oxidative stress level, nitric 
oxide (NO), and subsequent influence on lipid peroxidation in paraquat (PQ )-
induced Parkinsonian mouse model. MTTP-induced Parkinson mouse models 
were also studied by them for the reduction of estrogen by Mucuna pruriens  
[26, 55, 56]. Yadav et al. demonstrated that Mp seed extract reduces oxidative 
stress in nigrostriatal tissue and improves neurobehavioral activity and the 
expression of tyrosine hydroxylase (TH) in SN and striatum of the brain in 
PQ-intoxicated mice [56]. Apoptotic pathways of dopaminergic neurons in the 
PQ mouse model were also found to be inhibited by the neuroprotective activity 
of Mucuna pruriens [57]. Experiments also reveal that the Mucuna pruriens has 
a resilient anti-inflammatory property that diminishes the neuroinflammation 
by plummeting inducible nitric oxide synthase expression in Parkinsonian mice 
model. Symptomatic and neuroprotective efficacy in rodent model of Parkinson’s 
disease using Mucuna pruriens seed extract were studied by Kasture and Pontis 
[58]. Significance of M. pruriens in sperm parameters and sexual behavior of 
streptozotocin-induced diabetic male rat were studied by Sekar Suresh et al. [59]. 
Earlier efforts exhibited the capability of Mucuna pruriens seeds extract to induce 
contralateral turning behavior in the 6-hydroxydopamine (6-OHDA)-lesion 
persuaded rat model of PD [60]. Likewise, the potential of Mucuna seed powder 
extract significantly improved activity of brain mitochondrial complex-I without 
disturbing total monoamine oxidase activity in vitro [61]. Mucuna pruriens also has 
the potential to amend immune components like tumor necrosis factor-α (TNF-
α), interleukin-6 (IL-6), interferon-λ (IFN-λ), interleukin-1β (IL-1β), inducible 
nitric oxide synthase (iNOS), and interleukin-2 (IL-2) in the central nervous 
system, thereby, averting the progression of dopaminergic neurons degeneration, 
in PD [62]. Moreover M. pruriens was also assessed for levodopa pharmacokinetics 
by Sarrafchi et al., in a double-blinded clinical and pharmacological study. They 
observed that administration of M. pruriens at doses of 2.5, 5.0, or 10.0 g/kg/day 
for 52 weeks significantly increased the dopamine content of the cortex in animal 
model of PD. Therefore, they concluded that M. pruriens seed powder with natural 
source of levodopa probably has benefits over conventional levodopa preparations 
in treatment of PD due to its longer action and speedy onset without increase in 
adverse effect [63]. Thus, M. pruriens would seem to be a remarkable commercially 
viable alternative to standard L-dopa [64]. Likewise, an improvement in motor 
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skills and dyskinesia analogous to those induced by equivalent doses of L-DOPA 
was also found to be induced by M. pruriens preparations in rat and macaque 
monkey models of PD [61]. Therefore, all these studies strongly advocate the use 
of Mucuna pruriens: a treasurable herbal plant for treatment of PD.
2.2.4 Human trials
Copious studies have scrutinized the effect of MP in PD patients. The bioavail-
ability of L-DOPA in the central nervous system is about one-fifth when pooled 
with carbidopa or benserazide due to nonexistence of DOPA decarboxylase inhibi-
tor (DDCI) in Mucuna [61–65]. Even then, the first report in 1978 revealed that 
23 PD patients were treated with MP with similar effect and better tolerance than 
L-DOPA/benserazide. This study was followed by an open study where 60 PD 
patients in Hoehn and Yahr stage I–IV were treated with MP preparations for over 
12 weeks, which led to momentous headways in both UPDRS score and the Hoehn 
and Yahr stage. This captivated the attention on the registration of Mucuna prepara-
tion (Zandopa™) as a treatment for PD in India [61]. Cilia et al. executed a cross-
over study (N = 14) on PD patients in an advanced stage with motor fluctuations 
and peak-of-dose dyskinesia. The observations indicated better motor improvement 
on Mucuna powder consumption in comparison to the effect imparted by intake of 
an equivalent dose of L-DOPA/benserazide [66]. Innumerable experiments are still 
under investigation by several assemblages of researchers from all over the world 
to understand the PD progression and come up with innovative strategies to treat 
Parkinson’s disease [61, 62].
2.3 Other drugs and their effects
Gargantuan improvement has been done to treat the PD for over half-century. 
Diverse individuals from different places have come up with different treat-
ments. Miscellaneous categories of drugs are being used apart from levodopa. 
Yet to date there are no complete cure strategies for PD. But some symptomatic 
palliative treatments are being implemented to slow down the disease progres-
sion. There are various enzymes used in the management of PD. Enzymes 
monoamine oxidase-B (MAO-B) and catechol-o-methyl-transferase (COMT) are 
normally involved in metabolism of dopamine. Therefore, few inhibitors of the 
two enzymes (MAO-B and COMT) have been extensively studied. Inhibitors like 
selegiline, rasagiline, tolcapone, and entacapone are being used for the disease 
modification in PD from previous few years. N-propargyl-methamphetamine 
is known as selegiline, which is an irreversible inhibitor of MAO-B. Action of 
selegiline was studied in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-
induced Parkinsonism in monkeys [67]. It was used at concentration of 10 mg/
day, but they found that it loses its selectivity at higher concentrations of dosage 
[67]. Various other reports show the neuroprotective potential of selegiline but 
there is no such report proving that selegiline has “disease-modification” effects 
[68–70]. The in vitro and in vivo experimental Parkinsonian models indicate that 
rasagiline (N-propargyl-1-(R)-aminoindan) acted as irreversible MAOB inhibitor 
exhibiting anti-apoptotic effect [68–70].
There are various studies proving that the dopamine agonist or levodopa has 
stronger symptomatic benefits as the MAOB inhibitor; however, there was no evi-
dence of direct comparison between them [71–74]. Older people provide more rapid 
onset improvement than younger patients. Dopamine agonist is more prominent in 
younger people with dyskinesia and older people with orthostatic hypotension and 
CNS effects (hallucinations). Pharmacokinetic studies revel that COMT inhibitors 
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prevent degradation of peripheral levodopa by extending half-life and also permit 
it to cross the blood–brain barrier in higher concentrations. There are large number 
of compounds used to treat motor symptoms and motor complications occurring 
due to dopaminergic mode of action as reported in review by Oertel et al. Whereas 
carbidopa (modified form of L-dopa soluble), opicapone (COMT-inhibitor), 
safinamide (MAO-B-inhibitor), droxidopa (NMDA-receptor antagonist), strade-
fylline (noradrenaline precursor), tozadenant (Adenosine 2A receptor antago-
nist), pimavanserin (5HT2A inverse agonist), and donepezil (Acetyl choline 
esterase inhibitor) are some of the most common compounds used in the treatment 
internationally [16]. Along with benzhexol and orphenadrine, anticholinergic drugs 
are also recommended as they reduce the effect of acetylcholine in the brain by 
antagonizing cholinergic receptors and restore the acetylcholine/dopamine balance 
within the brain. They also prevent hyperkinesia.
3. Neurosurgical treatments
Apart from chemical drugs, there are some physical therapies involved in the 
treatment of PD that have given special attenuation toward movement (motor) 
symptoms of patient. In this treatment, parts of the brain involved in the progres-
sion of disease are either removed, bombard with electric impulse, or subjected to 
neuroimaging [75]. In pallidotomy and thalamotomy, the globus pallidus part of 
the brain, which is overactive in the PD patients, resulting in slackening down the 
body movements, is surgically destroyed permanently. This destruction of globus 
pallidus significantly reduces tremor, bradykinesia, balance problems, and writing 
problems, and eliminates rigidity, while thalamus part is involved in the involuntary 
movement (like tremor) [76, 77]. Deep brain stimulation (DBS) is also one of the 
unconventional treatments used, in which brain pace markers (microelectrode) are 
applied where an electrical impulse passes over the electrodes to the specific part of 
the brain. DBS decreases the secondary difficulties elevated due to dopaminergic 
replacement therapy. There are survival disadvantages of pallidotomy and thala-
motomy cases due to dysphagia, hypophonia, and dysarthria [78]. DBS is having 
significant results over thalamotomy because it does not need hardware and have 
very fewer side effects and relatively lowers the risk of complications. Besides all 
these pharmacological and surgical treatments, few other strategies like speech 
therapy, mediations are being currently explored along with it for the treatment of 
PD. Apart from singular therapy, doctors are now recommending a combination of 
treatments to impart cumulative effect in the treatment of PD.
4. Conclusion
Mucuna is a natural, rich source of precursor of dopamine that acts as gold 
standard for the treatment of Parkinson’s disease to control body movements, 
hormonal balance, emotion, and memory. The Mucuna is a pharmaceutically 
and biochemically valuable plant used from the early days, having high market 
value due to its large amount of bioactive compounds. It also contains a maximum 
amount of phenolics, flavonoids, and antioxidants, which have a cumulative role in 
the release of oxidative stress produced by body systems. Drosophila melanogaster, 
zebrafish, mice/rat, and human models were used to check the potential of Mucuna 
seed powder on rotenone, MPTP-induced Parkinson’s model, and it was concluded 
that Mucuna seeds have great values in the treatment of PD. The book chapter 
also covers various other drugs and neurosurgical treatments used in Parkinson’s 
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